Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
BM Turner & DG Hicks. (2017) Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy. Biotechnic & Histochemistry 92:3, pages 175-200.
Read now
Read now
Dg Hicks & B Turner. (2015) Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward “precision” cancer therapy. Biotechnic & Histochemistry 90:2, pages 81-92.
Read now
Read now
Alvin Eisner. (2015) Sex, Eyes, and Vision: Male/Female Distinctions in Ophthalmic Disorders. Current Eye Research 40:2, pages 96-101.
Read now
Read now
Articles from other publishers (26)
Kimberly H. Allison. 2024. Diagnostic Molecular Pathology. Diagnostic Molecular Pathology
303
318
.
Matthias Dietzel, Rubina Manuela Trimboli, Moreno Zanardo, Rüdiger Schultz-Wendtland, Michael Uder, Paola Clauser, Francesco Sardanelli & Pascal A. T. Baltzer. (2022) The potential of predictive and prognostic breast MRI (P2-bMRI). European Radiology Experimental 6:1.
Crossref
Crossref
Pramod Kumar Julka, Ishu Gupta & Romila Tiwari. 2022. Breast Cancer. Breast Cancer
425
441
.
Shuai Liu, Han Li, Qichen Zheng, Lu Yang, Meiyu Duan, Xin Feng, Fei Li, Lan Huang & Fengfeng Zhou. (2021) Survival Time Prediction of Breast Cancer Patients Using Feature Selection Algorithm Crystall. IEEE Access 9, pages 24433-24445.
Crossref
Crossref
Maria Clara Rodriguez Palleiro & Gabriel Krygier Waltier. (2020) The impact of 21‐Gene Recurrence Score test and classic clinical‐pathologic factors in guiding adjuvant therapy for HER‐2 negative, ER‐positive, early‐stage breast cancer: A retrospective study. The Breast Journal 26:5, pages 1064-1066.
Crossref
Crossref
Carla Rognoni, Silvana Quaglini, Jan Baptist Vermorken, Loris De Cecco, Lisa Licitra & Paolo Bossi. (2019) Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. Clinical Therapeutics 41:12, pages 2517-2528.e28.
Crossref
Crossref
Kyung Jin Nam, Hyunjin Park, Eun Sook Ko, Yaeji Lim, Hwan-Ho Cho & Jeong Eon Lee. (2019) Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers. Medicine 98:23, pages e15871.
Crossref
Crossref
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Olivier Brouckaert, Hans Wildiers, Giuseppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, Robert Paridaens, Anita Giobbie-Hurder, Meredith M. Regan, Giuseppe Viale, Beat Thürlimann, Ignace Vergote, Evangelia Christodoulou, Ben Van Calster & Patrick Neven. (2019) Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. The Oncologist 24:2, pages 165-171.
Crossref
Crossref
Ann E. Walts, James M. Mirocha & Shikha Bose. (2018) Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers. The Breast Journal 24:6, pages 951-956.
Crossref
Crossref
Christos Markopoulos. 2018. Breast Cancer Management for Surgeons. Breast Cancer Management for Surgeons
89
101
.
Yun Li, Allison W. Kurian, Irina Bondarenko, Jeremy M. G. Taylor, Reshma Jagsi, Kevin C. Ward, Ann S. Hamilton, Steven J. Katz & Timothy P. Hofer. (2016) The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Breast Cancer Research and Treatment 161:3, pages 587-595.
Crossref
Crossref
Michaela Aubele, Manfred Schmitt, Rudolf Napieralski, Stefan Paepke, Johannes Ettl, Magdalena Absmaier, Viktor Magdolen, John Martens, John A. Foekens, Olaf G. Wilhelm & Marion Kiechle. (2017)
The Predictive Value of
PITX2
DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
. Disease Markers 2017, pages 1-14.
Crossref
Crossref
K.H. Allison. 2017. Diagnostic Molecular Pathology. Diagnostic Molecular Pathology
257
269
.
Christopher R. Friese, Yun Li, Irina Bondarenko, Timothy P. Hofer, Kevin C. Ward, Ann S. Hamilton, Dennis Deapen, Allison W. Kurian & Steven J. Katz. (2017) Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer. Cancer 123:1, pages 43-51.
Crossref
Crossref
Juliette Plun-Favreau, Kaisa Immonen-Charalambous, Lotte Steuten, Anja Strootker, Roman Rouzier, Denis Horgan & Mark Lawler. (2016) Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?. Public Health Genomics 19:3, pages 144-152.
Crossref
Crossref
Ina Han Lee. (2016) Molecular Prognostic and Predictive Assays in Breast Cancer. AJSP: Review and Reports 21:1, pages 4-10.
Crossref
Crossref
François-Michel Delgado, Maria Angeles Gil-Delgado & David Khayat. 2016. Induction Chemotherapy. Induction Chemotherapy
131
156
.
Lillian Smyth, Geoff Watson, Elaine M. Walsh, Catherine M. Kelly, Maccon Keane, M. John Kennedy, Liam Grogan, Bryan T. Hennessy, Seamus O’Reilly, Linda E. Coate, Miriam O’Connor, Cecily Quinn, Katharina Verleger, Olaf Schoeman, Susan O’Reilly & Janice M. Walshe. (2015) Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. Breast Cancer Research and Treatment 153:3, pages 573-582.
Crossref
Crossref
Michael J Duffy, Catharine M Sturgeon, György Sölétormos, Vivian Barak, Rafael Molina, Daniel F Hayes, Eleftherios P Diamandis & Patrick M M Bossuyt. (2015) Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. Clinical Chemistry 61:6, pages 809-820.
Crossref
Crossref
Xavier Pivot, Laura Mansi, Loic Chaigneau, Philippe Montcuquet, Antoine Thiery-Vuillemin, Fernando Bazan, Erion Dobi, Jean L. Sautiere, Frederic Rigenbach, Marie P. Algros, Steve Butler, Farid Jamshidian, Phillip Febbo, Christer Svedman, Sophie Paget-Bailly, Franck Bonnetain & Christian Villanueva. (2015) In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?. The Oncologist 20:4, pages 344-350.
Crossref
Crossref
Daniel Schneider, Giampaolo Bianchini, Denis Horgan, Stefan Michiels, Wim Witjes, Robert Hills, Juliette Plun-Favreau, Angela Brand & Mark Lawler. (2015) Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Public Health Genomics 18:6, pages 349-358.
Crossref
Crossref
Noa Eyal, Mark Last & Eitan Rubin. (2015) Comparison of three classifiers for breast cancer outcome prediction. Comparison of three classifiers for breast cancer outcome prediction.
Terri Patricia McVeigh, Lauren M. Hughes, Nicola Miller, Margaret Sheehan, Maccon Keane, Karl J. Sweeney & Michael J. Kerin. (2014) The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. European Journal of Cancer 50:16, pages 2763-2770.
Crossref
Crossref
Charles L. Vogel, Mary Ann Johnston, Christi Capers & Deborah Braccia. (2014) Toremifene for Breast Cancer: A Review of 20 Years of Data. Clinical Breast Cancer 14:1, pages 1-9.
Crossref
Crossref
D.C. Anderson & Krishna Kodukula. (2014) Biomarkers in pharmacology and drug discovery. Biochemical Pharmacology 87:1, pages 172-188.
Crossref
Crossref
BAHRIYE AKTAS, AGNES BANKFALVI, MARTIN HEUBNER, RAINER KIMMIG & SABINE KASIMIR-BAUER. (2013) Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX®, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. Molecular and Clinical Oncology 1:6, pages 1049-1054.
Crossref
Crossref